Matthijs M. Tibben

Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy

Suzanne Leijen, Sjaak A. Burgers, Dick Pluim et al. · Investigational New Drugs · 2014 · 366 citations · Full text

Medicine, Oncology, Pharmacology +12

Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles

Pauline Breedveld, Noam Zelcer, Dick Pluim et al. · Cancer Research · 2004 · 233 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin

Jetske M. Meerum Terwogt, Gerard Groenewegen, Dick Pluim et al. · Cancer Chemotherapy and Pharmacology · 2002 · 122 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin

Alwin D. R. Huitema, Manon C.W. Spaander, Ron A. A. Mathôt et al. · Annals of Oncology · 2002 · 64 citations · Full text

Pharmacy, Oncology, Pharmacology +12

Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry

Alejandra Martínez-Chávez, Hilde Rosing, M. J. X. Hillebrand et al. · Analytical and Bioanalytical Chemistry · 2019 · 64 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17